The global TIL therapy market is expected to reach USD 0.09 billion in 2023 anticipated to grow at a CAGR of 40% during the forecast period 2023-2035.

The global market for tumor infiltrating lymphocytes (TIL) therapy stands as a pivotal subset within the expansive realm of cell therapy. Projections suggest a significant upward trajectory, with an anticipated Compound Annual Growth Rate (CAGR) of 40% throughout the forecast period.

The efficacy of tumor infiltrating lymphocytes (TILs) in addressing refractory diseases has garnered robust support from an array of comprehensive studies conducted over time. TILs encompass a heterogeneous amalgamation of mononuclear lymphocytes, inclusive of T-cells, B-cells, NK cells, and macrophages meticulously extracted from the tumor microenvironment. This diverse spectrum of lymphocytes assumes a critical role in targeting and eliminating tumor cells.

Ongoing and prospective clinical research endeavors in this field are driven by the promising outcomes derived from previous trials, predominantly focusing on a wide spectrum of solid tumors. The sustained momentum of innovation in this arena, backed by substantial financial support from investors, combined with encouraging findings from clinical trials, lays the groundwork for substantial growth within the TIL therapy market throughout the forecasted period.

Report Coverage
? An executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the TIL-based therapies market in the short to mid-term and long term.
? A general overview of TIL-based therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of TIL-based therapies, factors supporting the growing popularity of such therapy candidates and the challenges associated with these products.
? Detailed assessment on more than 65 TIL-based therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer, phase of development, therapeutic area, popular target indications, source of T-cells, dose frequency, target patient segment and type of therapy.
? An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2?2 matrix representation highlighting the KOLs shortlisted based on their contributions to this field, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers involved in the development of TIL-based therapies.
? Detailed profiles of TIL-based therapies in developmental stages (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, current development status, and key clinical trial results.
? An elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed based on various parameters, such as type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.
? Details on the various investments and grants that have been awarded to players focused on the development of TIL-based therapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.
? Insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites.
? Details on the various factors that must be taken into consideration while deciding the prices of TIL-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their TIL-based therapy product can be marketed.
? Brief company profiles of the leading players in the TIL-based therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to technology portfolio (if available), recent developments related to TIL-based therapy and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
? An elaborate discussion on the future commercial opportunity offered by TIL-based therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II and phase II of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. It presents a detailed market segmentation based on target indications (melanoma, head and neck cancer, breast cancer, hepatocellular cancer, sarcoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and cervical cancer), key players and key geographies (North America, Europe and Asia Pacific).

Key Market Companies
? Cellectis
? Cellular Biomedicine Group
? Iovance Biotherapeutics
? Lytix Biopharma
? Phio Pharmaceuticals